Spirometric abnormalities in patients with Fabry disease and effect of enzyme replacement therapy

Détails

ID Serval
serval:BIB_983C8C910B4B
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Poster: résume de manière illustrée et sur une page unique les résultats d'un projet de recherche. Les résumés de poster doivent être entrés sous "Abstract" et non "Poster".
Collection
Publications
Institution
Titre
Spirometric abnormalities in patients with Fabry disease and effect of enzyme replacement therapy
Titre de la conférence
4th International Symposium on Lysosomal Storage
Auteur(s)
Barbey F., Widmer U., Brack T.H., Vogt B., Aubert J.D.
Adresse
Seville, Spain, April 23-24, 2004
Statut éditorial
Publié
Date de publication
2005
Volume
94
Série
Acta Paediatrica
Pages
105
Langue
anglais
Résumé
Aim: Fabry disease is an X-linked genetic disorder due
to deficiency of the lysosomal enzyme a-galactosidase
A, which leads to the accumulation of neutral glycosphingolipids
within the lysosomes of almost all tissues.
Clinical manifestations usually include acroparaesthesia,
renal insufficiency and cardiomyopathy.
Recently, pulmonary manifestations consisting of
progressive obstructive airway disease have been
reported. The aim of this study was to analyse the
cross-sectional prevalence of airflow obstruction in a
Swiss cohort of patients, and in selected cases, to
evaluate the impact of enzyme replacement therapy
(ERT) with agalsidase alfa (ReplagalTM; TKT - 5S).
Methods: Forty-four patients (27 men, 17 women)
were included in the study and received pulmonary
function testing. Fifteen patients underwent spirometry
after ERT.
Results: Twelve patients (nine men) had chronic
obstructive pulmonary disease according to the
Global Obstructive Lung Disease (GOLD) initiative
criteria: forced expiratory volume (FEV1)/forced
vital capacity (FVC) 50.7), but only one was an
active smoker and one a previous smoker. FEV1/
FVC as percentage predicted was weakly correlated
with age (r=0.42, p=0.005, calculated by Pearson
product-moment correlation), demonstrating that
airway obstruction occurs in the late stages of the
disease. Median FEV1 in patients with obstruction
was 67% of predicted (range, 45-90%). Reversibility
of FEV1 after b2-agonist inhalation never exceeded
8% of predicted. Diffusing capacity of the lung for
carbon monoxide (DLCO) was measured in 13
individuals with a median of 88% of predicted
(range, 39-125%). After 15+9 months of ERT,
spirometry measurements were recorded in 15
patients. Decline in FEV1 was -2+5% of predicted.
(p40.05, measured by the Wilcoxon signed-rank
test). Median change in DLCO was -10% of
predicted (-40 to +25%, p40.05). High resolution
computed tomography scans demonstrated a moderate
thickening of the bronchial wall in affected
individuals, without evidence of emphysema.
Conclusion: We conclude that Fabry disease can be
complicated by significant airway obstruction, particularly
in patients in the advanced stages of the disease,
and that in the period studied, ERT had no demonstrable
impact on pulmonary function.
Création de la notice
09/02/2012 17:50
Dernière modification de la notice
20/08/2019 14:59
Données d'usage